U.S. Medical Equipment Stock News

NYSE:SCL
NYSE:SCLChemicals

How Stepan’s Swing to Q1 Loss With Steady Dividend At Stepan (SCL) Has Changed Its Investment Story

Stepan Company reported past first-quarter 2026 results showing sales of US$604.51 million versus US$593.26 million a year earlier, but it swung from net income of US$19.71 million to a net loss of US$41.41 million, with basic and diluted loss per share from continuing operations of US$1.81 compared with earnings of US$0.86. Despite the move into loss-making territory, Stepan maintained its shareholder payout by affirming a quarterly dividend of US$0.395 per share, payable on June 15, 2026,...
NYSE:IHS
NYSE:IHSTelecom

IHS Holding Sells I‑Systems Stake And Refocuses On Core Tower Assets

IHS Holding (NYSE:IHS) has completed the divestment of its 51% stake in Brazilian fiber infrastructure venture I-Systems. The stake has been sold to TIM S.A., marking IHS Holding's exit from this Brazilian optical fiber joint venture. IHS Holding, trading at $8.23, has seen its stock return 12.0% year to date and 44.1% over the past year, while its 3 year return stands at 9.2%. This completed I-Systems divestment gives investors a fresh development to consider alongside those share price...
NYSE:ALB
NYSE:ALBChemicals

Albemarle Votes Reshape Governance While Dividend And Cash Flows Steady

Albemarle (NYSE:ALB) held its annual shareholder meeting on May 5, 2026. Shareholders approved the board slate, executive compensation package, and auditor ratification. A proposal to remove supermajority provisions for certain affiliated transactions narrowly did not pass. Shareholders backed a proposal to make it easier for investors to call special meetings. Albemarle, a major producer in the lithium and specialty chemicals space, sits at the center of debates around corporate governance...
NYSE:MMS
NYSE:MMSProfessional Services

Has The Market Mispriced Maximus (MMS) After Its Recent 22.9% Year-To-Date Decline?

Wondering if Maximus stock is offering fair value or a potential bargain right now, especially after a tough stretch for returns. The share price last closed at US$66.66, with Maximus delivering a 1.6% return over the past week and 2.3% over the last month, but a 22.9% decline year to date and a 10.6% decline over the last year hint at changing sentiment. Recent coverage has focused on how Maximus fits into investors' long term portfolios and whether the current price reflects its...
NYSE:RNR
NYSE:RNRInsurance

RenaissanceRe Chair Change And Renewed Buybacks Focus Attention On Capital Use

RenaissanceRe Holdings (NYSE:RNR) has appointed Henry Klehm III as Non-Executive Chair, succeeding the company’s long-serving board leader. The board also renewed its share repurchase program, authorizing up to $750 million of buybacks. These moves highlight changes in board oversight and capital allocation at a time when the stock trades around $300.84. RenaissanceRe Holdings comes into this leadership change with the stock at $300.84 and multi year share price gains, including 10.5% year...
NYSE:DNOW
NYSE:DNOWTrade Distributors

Is DNOW (DNOW) Worth Another Look After Its Recent Share Price Weakness

If you are wondering whether DNOW stock offers value at today’s price, the key question is how that price lines up with the company’s underlying fundamentals. The stock last closed at US$13.05, with returns of 6.3% over 30 days, a 3.3% decline over 7 days, a 2.3% decline year to date, and a 10.2% decline over 1 year. The 3 year and 5 year returns sit at 43.1% and 19.8% respectively. These mixed returns highlight that sentiment around DNOW can shift over different time frames. This often...
NYSE:DX
NYSE:DXMortgage REITs

Is Dynex Capital (DX) Pricing Look Attractive After Recent Share Price Swings?

If you are wondering whether Dynex Capital's current share price offers good value or carries more risk than reward, the starting point is to look closely at how it stacks up on valuation. The stock recently closed at US$13.32, with a 7 day return of 2.2% decline, a 30 day return of 5.0%, a year to date return of 5.4% decline, and a 1 year return of 25.5%, which gives you a mix of short term setbacks and longer term gains to weigh up. Recent coverage around Dynex Capital has focused on how...
NasdaqGS:XERS
NasdaqGS:XERSPharmaceuticals

A Look At Xeris Biopharma Holdings (XERS) Valuation After Its Profit Turnaround And Guidance Hike

Xeris Biopharma Holdings (XERS) stock is in focus after the company reported a profitable first quarter of 2026 and raised its full year revenue guidance to US$380 million to US$390 million. See our latest analysis for Xeris Biopharma Holdings. The guidance hike and first quarter profit have come after a mixed period for the stock, with a 12.95% 1 month share price return and a 9.80% year to date share price decline. At the same time, 1 year and 3 year total shareholder returns of 28.49% and...
NasdaqGS:WDC
NasdaqGS:WDCTech

3 High ROE Stocks With Rock Solid Balance Sheets To Watch

Inflation jitters, higher energy costs and uneven global growth are putting a spotlight on company quality. When price pressures, shifting trade flows and rate expectations keep markets on edge, stocks with high return on equity, solid past performance and strong balance sheets can offer a more direct way to focus on business strength rather than noise. This article uses our Solid Balance Sheet and Fundamentals screener to highlight 3 stocks that fit this quality filter, helping you focus on...
NYSE:FLR
NYSE:FLRConstruction

If The Nuclear Renaissance Is Real These Three Backlogs Matter

Rising inflation surprises, volatile energy and food prices, and mixed signals on growth are keeping markets jumpy, while the world’s appetite for electricity-intensive AI and low carbon power keeps building. For investors, that combination puts long term, round the clock clean energy at the center of many big spending plans. The Nuclear Renaissance screener focuses on companies tied to this push for reliable, carbon free power linked to major infrastructure commitments rather than short term...
NasdaqCM:ALTO
NasdaqCM:ALTOChemicals

A Look At Alto Ingredients (ALTO) Valuation After Its Q1 2026 Earnings Turnaround

Q1 earnings turnaround draws fresh attention Alto Ingredients (ALTO) has caught investor interest after reporting first quarter 2026 net income of US$4.27 million, a shift from an US$11.68 million net loss in the same period a year earlier. Sales for the quarter were US$224.68 million compared with US$226.54 million a year ago, while both basic and diluted earnings per share from continuing operations came in at US$0.05 versus a basic and diluted loss per share of US$0.16 previously. See our...
NYSE:CHD
NYSE:CHDHousehold Products

The Bull Case For Church & Dwight (CHD) Could Change Following Flat Q1 Results And Rising E-Commerce Mix

Church & Dwight Co., Inc. recently reported first-quarter 2026 results showing sales of US$1,469.3 million and net income of US$216.3 million, affirmed a quarterly dividend of US$0.3075 per share, and issued guidance for a 1% reported sales decline for the June 2026 quarter due to prior portfolio actions. Management highlighted that growth in key brands such as ARM & HAMMER and THERABREATH, alongside online sales reaching nearly 24% of global consumer sales, is supporting underlying...
NYSE:G
NYSE:GProfessional Services

Is Genpact (G) Now An Opportunity After Recent Share Price Weakness?

If you are wondering whether Genpact at around US$34.48 is a bargain or a value trap, the key is understanding what the current price really reflects. Over the short term, the stock has seen a 0.8% decline over 7 days, an 8.0% decline over 30 days, and is down 24.9% year to date, with a 16.6% decline over 1 year and a near flat 0.3% return over 3 years, compared with a 17.0% decline over 5 years. Recent coverage around Genpact has focused on how the business is positioned in professional...
NasdaqGS:RJET
NasdaqGS:RJETAirlines

Assessing Republic Airways Holdings (RJET) Valuation After Recent Share Price Momentum

What Republic Airways Holdings (RJET) Offers Investors Today Republic Airways Holdings (RJET) operates scheduled passenger services with about 275 aircraft and 1,300 daily flights across 130 cities in the United States, Canada, the Caribbean, and Mexico. The company reported revenue of US$1,809.1 million and net income of US$76.0 million. The stock most recently closed at US$22.39, with reported returns of 10.51% over the past day, 34.39% over the past week, 21.82% over the past month, and...
NYSE:SES
NYSE:SESElectrical

Assessing SES AI (SES) Valuation As Shares Slide And Revenue Growth Expectations Build

SES AI stock performance snapshot SES AI (SES) has drawn fresh attention as investors reassess high risk battery technology stocks, with the share price recently closing at US$0.92 and the market cap sitting near US$362.7m. See our latest analysis for SES AI. The recent 1 day share price return of a 6.24% decline, alongside a 7 day share price return of a 12.29% decline and a 90 day share price return of a 51.01% decline, contrasts with a 1 year total shareholder return of 2.19%. This...
NYSE:EVEX
NYSE:EVEXAerospace & Defense

A Look At Eve Holding (EVEX) Valuation After Q1 2026 Loss And eVTOL Commercialization Updates

Q1 2026 earnings put Eve Holding in focus Eve Holding (EVEX) is back on investors’ radar after reporting a wider first quarter 2026 loss, updating its eVTOL commercialization timeline, and outlining progress on certification and prototype flight testing. See our latest analysis for Eve Holding. The earnings update and prototype milestones have come after a mixed run for the stock, with a 24.9% 1 month share price return but a 23.39% year to date share price decline and a 59.82% 3 year total...
NYSE:CXT
NYSE:CXTElectronic

A Look At Crane NXT (CXT) Valuation As Q1 Earnings And Antares Vision Deal Beat Expectations

Why Crane NXT stock is back in focus after Q1 Crane NXT (CXT) is drawing fresh attention after first quarter 2026 revenue and adjusted earnings topped expectations, helped by the Antares Vision acquisition and firm demand in Security and Authentication Technologies. See our latest analysis for Crane NXT. The latest results and acquisition update have arrived after a mixed share price run, with a 30 day share price return of 5.40% but a 1 year total shareholder return decline of 12.80%. If Q1...
NasdaqGS:CARG
NasdaqGS:CARGInteractive Media and Services

Can CarGurus’ AI Push and Dealer Focus Redefine Its Core Marketplace Edge (CARG)?

CarGurus, Inc. has now reported its past first-quarter 2026 results, posting sales of US$243.56 million versus US$212.24 million a year earlier, while net income eased to US$32.23 million from US$39.05 million and diluted EPS from continuing operations slipped to US$0.34 from US$0.40. Alongside this, CarGurus highlighted AI-led product investment, broader premium-tier adoption, a multi-year NASCAR Canada partnership, new data-driven Confidence Awards, and ongoing share repurchases,...
NYSE:MBC
NYSE:MBCBuilding

MasterBrand (MBC) Is Down 12.9% After Q1 Loss And Lower Q2 Outlook Has The Bull Case Changed?

In the past quarter, MasterBrand, Inc. reported Q1 2026 sales of US$618 million, down from US$660.3 million a year earlier, and moved from a net income of US$13.3 million to a net loss of US$15.4 million. Alongside weaker results, the company guided to a further mid- to high-single-digit year-over-year sales decline for Q2 2026 and confirmed it repurchased 226,914 shares under its 2025 buyback plan while advancing cost cuts and tariff mitigation as it works toward a merger with American...
NYSE:IDA
NYSE:IDAElectric Utilities

The Bull Case For IDACORP (IDA) Could Change Following Reaffirmed 2026 EPS Guidance And Q1 Beat

IDACORP, Inc. reported past first-quarter 2026 results showing sales of US$402.76 million and net income of US$67.98 million, with diluted EPS from continuing operations of US$1.21, up from US$1.10 a year earlier. Alongside reaffirming its full-year 2026 earnings guidance of US$6.25 to US$6.45 per diluted share, the company expects Idaho Power to use less than US$30 million of additional tax credits under its Idaho regulatory mechanism, assuming normal weather and power supply expenses. We...
NYSE:USPH
NYSE:USPHHealthcare

A Look At U.S. Physical Therapy’s Valuation After Mixed Q1 2026 Earnings And Share Price Weakness

Quarterly results and dividend announcement set fresh context for U.S. Physical Therapy U.S. Physical Therapy (USPH) reported first quarter 2026 revenue of US$198.29 million, compared with US$183.79 million a year earlier. Net income was US$5.04 million, versus US$9.9 million in the prior-year period, alongside a reaffirmed quarterly dividend. See our latest analysis for U.S. Physical Therapy. The earnings release appears to have reset expectations, with the stock’s 1 day share price return...
NasdaqCM:PSIX
NasdaqCM:PSIXElectrical

How Investors May Respond To Power Solutions International (PSIX) Data Center Capacity Misstatement Lawsuits

In recent months, multiple law firms have launched securities class action lawsuits against Power Solutions International, alleging false and misleading statements about its ability to meet data center sales demand and manage related manufacturing costs between May 2025 and March 2026. The wave of similar complaints highlights how disclosures about operational inefficiencies and gross margin pressure can rapidly shift legal, operational, and governance risks for shareholders. Next, we’ll...
NYSE:CVSA
NYSE:CVSAConsumer Services

Will Covista’s (CVSA) AI Healthcare Pivot With Google Cloud and Earnings Beat Change Its Narrative?

Covista Inc. has already reported third-quarter fiscal 2026 results, with sales rising to US$487.03 million while net income eased to US$41.64 million, and announced an AI-powered healthcare education partnership with Google Cloud that is drawing strong interest in its new professional certificate programs. Together, the earnings beat, higher full-year guidance and rapid uptake of the AI-enabled courses suggest Covista is increasingly leaning on higher-margin digital offerings to support its...
NasdaqGM:SUPN
NasdaqGM:SUPNPharmaceuticals

Supernus Pharmaceuticals (SUPN) Is Up 8.9% After Q1 Beat And Reaffirmed 2026 Outlook Has The Bull Case Changed?

In early May 2026, Supernus Pharmaceuticals, Inc. reported first-quarter 2026 results showing revenue of US$207.71 million versus US$149.82 million a year earlier, with net loss narrowing to US$2.29 million from US$11.83 million. On the same day, the company reiterated its full-year 2026 outlook, projecting total revenues of US$840 million–US$870 million and operating earnings of US$0–US$30 million, signalling management’s confidence in its current trajectory. We’ll now examine how...